Advent Life Sciences, established in 2006, is a London-based venture capital firm specializing in life sciences investments. With a team of 11 professionals boasting extensive scientific, medical, and operational experience, the firm focuses on early and growth-stage companies across the UK, Europe, and the US. Advent Life Sciences invests in a range of sectors, including new drug discovery, med tech, and enabling technologies. Notable exits in recent years include Algeta, Avila, and EUSA. Current investments span companies like Acutus, Biocartis, and f2G. The firm is known for its partnership approach, working closely with entrepreneurs to build valuable businesses.
Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.
Epitopea
Seed Round in 2022
Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.